Introduction: Congestive heart failure (CHF) is a major global health challenge and the leading cause of hospitalization in the U.S., with disproportionately high 30-day readmission rates among low-income and minority communities. Social drivers of health and substance use both influence CHF outcomes, yet the effect of substance use on short-term readmissions remains understudied. This study evaluated the association between substance use and all-cause 30-day readmissions at a Safety-Net Community Hospital. Methods: A retrospective chart review was conducted among 500 adults admitted with CHF between 2019 and 2021. Substance use was defined as any documented use, identified through a positive urine toxicology or patient-reported social history of cocaine, tetrahydrocannabinol (THC), opioids, amphetamines, benzodiazepines, barbiturates, methadone, or phencyclidine (PCP). Alcohol and tobacco were assessed separately. Group differences were assessed using Chi-square and Wilcoxon rank-sum tests. Multivariable logistic regression was used for 30-day readmissions, and multivariable Poisson regression was used for total hospitalizations and length of stay (LOS). Results: Evidence of substance use was present in 38% of patients, with cocaine and THC most common. Patients with a history of substance use were younger, more often male, and experienced greater socioeconomic disadvantage. They had higher all-cause 30-day readmissions (21% vs. 14%; p = 0.048), more total hospitalizations (median 2 vs. 1 stay; p < 0.0001), and shorter LOS (median 4 vs. 5 days; p = 0.04). No differences were observed in 7-day post-hospitalization. Conclusions: Substance use is common among CHF patients at a safety-net hospital and was associated with higher 30-day readmissions as well as shorter hospital stays, which may reflect premature discharge rather than improved recovery. Future studies should assess whether addressing substance use alongside socioeconomic disparities can reduce readmissions in this population.
Background and Objectives: Heart failure (HF) often leads to worsening renal function (WRF), negatively impacting patient outcomes. This study aims to examine the incidence of WRF in HF patients, identify its risk factors, and assess its effect on readmissions. Materials and Methods: This retrospective analysis included 297 HF patients admitted to Harlem Hospital Center between January 2019 and December 2021. WRF incidence and its association with risk factors, hospital stays, and readmissions were analyzed. Data on age, type 2 diabetes, chronic kidney disease, high-dose furosemide use, and biomarkers (ProBNP, troponin T, creatinine) were collected. A risk-scoring system was developed to identify patients at higher risk for WRF. Results: WRF occurred in 27% of patients, with a significant correlation to longer hospital stays and lower cardiology follow-up adherence. Risk factors for WRF included older age, type 2 diabetes, chronic kidney disease, high-dose furosemide, and elevated ProBNP, troponin T, and creatinine levels. The risk scoring system revealed that patients scoring 6 or higher were four times more likely to develop WRF. Interestingly, WRF did not increase 30-day readmission rates. Conclusions: This study highlights the high incidence of WRF among HF patients, its impact on hospital stays and follow-up adherence, and the utility of a risk-scoring system to identify vulnerable patients. The findings offer valuable insights into improving care in minority-serving hospitals and provide a foundation for future research on WRF in HF patients.
Introduction: CHF is defined as a chronic disease that impacts more than 5 million adults in the United States with significant population-wide impact on morbidity, mortality and hospitalization burden, especially amonth high-risk and vulnerable populations. Although the intricacies of CHF and readmission risk have been well documented, there have been fewer studies investigating the effect of illicit drug use on CHF patients and readmission outcomes especially in a population at high risk of health disparities. Objective: The purpose of this study was to examine the effects of illicit drug use on CHF patients and hospital readmission rates at Harlem Hospital Center with a high density of patients with health disparities. Methods: We included all patients admitted during a 2 year period (2019-2020) with a primary diagnosis of heart failure to Harlem Hospital Center and conducted in depth assessment of drug use history including patient history, available laboratory analysis, and collateral EMR information. Rehospitalization was assessed by review of EMR by trained medical professionals. Our results were analyzed using standard statistical methods between the two groups with and without history of drug use. Results: Our study population included 380 admitted CHF patients. The overall prevalence of illicit drug use in CHF patients was 32.89%, with the most common drug used being cocaine. CHF patients who used illicit drugs had a 22.58% 30-day readmission rate in comparison to 13.78% among CHF patients who didn’t use illicit drugs. In addition, CHF patients who used illicit drugs had higher all-time hospitalizations and were more likely to be admitted than non-illicit drug users in terms of heart failure hospitalizations. Overall, CHF patients who used any type of illicit drug were twice as likely to be readmitted after index hospitalization compared to CHF patients who didn’t use illicit drugs. We also found that CHF patients who used illicit drugs were slightly younger, more likely to be male, and more likely to smoke cigarettes. Lastly, we observed that at least 50% of CHF patients who used illicit drugs were on government assistance, lacked family support, and were unemployed. Conclusion: Drug use is a common problem among patients with CHF in this vulnerable population and is associated with significant adverse outcomes such as increased rehospitalization. Systemic efforts to address this at the patient and community level are justified.